GT Biopharma (GTBP) Return on Equity [ROE] (2017 - 2026)
GT Biopharma's Return on Equity [ROE] came in at -289.86% for Q2 2026, down 91.71 percentage points from the prior quarter.
Powered by 
Analysis
GT Biopharma (GTBP) Return on Equity [ROE] (2017 - 2026) Analysis & Trends
For FY2025, GT Biopharma's Return on Equity [ROE] was -603.64%, down 122.69 percentage points from FY2024.
- Return on Equity [ROE] has declined in each of the last three years, with a three-year change of -478.97 percentage points (FY2022 to FY2025).
- Going back by year, Return on Equity [ROE] was -480.95% in FY2024 (-345.51 pp), -135.44% in FY2023 (-10.76 pp) and -124.68% in FY2022.
- The Q2 2026 figure represents the lowest quarterly Return on Equity [ROE] since Q4 2024.
- The fastest year-over-year change in Return on Equity [ROE] over five years came in Q4 2025 (a gain of 6259.64 percentage points), and the weakest in Q4 2024 (a drop of 6390.74 percentage points).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,359.75 Bn | 1,333.37 Bn | 20.46 Bn | 74.39% |
| 2 | Johnson & Johnson | 688.76 Bn | 608.62 Bn | 17.30 Bn | 19.33% |
| 3 | AbbVie | 521.69 Bn | 489.75 Bn | 13.12 Bn | - |
| 4 | Merck | 364.31 Bn | 327.31 Bn | 13.19 Bn | 5.63% |
| 5 | Novartis Ag | 306.35 Bn | 279.93 Bn | - | - |
| 6 | Astrazeneca | 285.96 Bn | 259.56 Bn | 13.26 Bn | 21.60% |
| 7 | Amgen | 251.88 Bn | 203.53 Bn | 7.58 Bn | 72.13% |
| 8 | Gilead Sciences | 208.59 Bn | 183.61 Bn | 6.73 Bn | -31.17% |
| 9 | Pfizer | 164.73 Bn | 112.38 Bn | 12.56 Bn | 4.66% |
| 10 | GT Biopharma | 6.65 Mn | -16.58 Mn | - | -289.86% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -289.86% |
| Mar 31, 2026 | -198.14% |
| Dec 31, 2025 | -279.94% |
| Dec 31, 2024 | -6,539.58% |
| Sep 30, 2024 | -348.35% |
| Jun 30, 2024 | -233.72% |
| Mar 31, 2024 | -191.51% |
| Dec 31, 2023 | -148.84% |
| Sep 30, 2023 | -141.09% |
| Jun 30, 2023 | -157.80% |
| Mar 31, 2023 | -155.15% |
| Dec 31, 2022 | -151.44% |
| Sep 30, 2022 | -215.48% |
| Jun 30, 2022 | -124.83% |
| Mar 31, 2022 | -67.05% |
| Dec 31, 2021 | -139.65% |
| Sep 30, 2021 | 3.53% |
| Jun 30, 2021 | -9.30% |
| Jun 30, 2019 | -2,604.39% |
| Mar 31, 2019 | -2,371.69% |
API Access
GT Biopharma Return on Equity [ROE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=GTBP&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-equity-[roe]", "ticker": "GTBP", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=GTBP&period=max&api_key=YOUR_API_KEY");
const data = await res.json();